Last reviewed · How we verify
Heparin & aspirin
Heparin and aspirin work synergistically to prevent blood clots by inhibiting coagulation cascade and platelet aggregation respectively.
Heparin and aspirin work synergistically to prevent blood clots by inhibiting coagulation cascade and platelet aggregation respectively. Used for Thromboprophylaxis in acute coronary syndrome, Prevention of venous thromboembolism, Acute myocardial infarction management.
At a glance
| Generic name | Heparin & aspirin |
|---|---|
| Also known as | LMWH & Ecoaspirin |
| Sponsor | Dr.Vandana Bansal |
| Drug class | Anticoagulant and antiplatelet combination |
| Target | Thrombin, Factor Xa, COX-1 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Heparin is an anticoagulant that enhances antithrombin III activity to inhibit thrombin and factor Xa, preventing fibrin formation. Aspirin irreversibly inhibits cyclooxygenase (COX) to reduce thromboxane A2 production and platelet aggregation. Together, they provide dual anticoagulant and antiplatelet effects for thromboprophylaxis.
Approved indications
- Thromboprophylaxis in acute coronary syndrome
- Prevention of venous thromboembolism
- Acute myocardial infarction management
Common side effects
- Bleeding
- Thrombocytopenia
- Gastrointestinal hemorrhage
- Heparin-induced thrombocytopenia (HIT)
Key clinical trials
- Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility
- Bariatric Surgery for the Reduction of cArdioVascular Events Randomized Controlled Trial (NA)
- Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE) (PHASE3)
- To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction. (PHASE3)
- LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention (PHASE4)
- Effect of Telitacicept on Antibody Titers in Primary APS Patients (PHASE2)
- Delivery and Implementation of a Randomised Crossover Trial on Thrombosis (NA)
- Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |